Introduction Shanghai HyaMab Biotechnology Co., Ltd., headquartered in Shanghai's Zhangjiang Innovation Cluster Pharmaceutical Valley, is focused on developing new anti-cancer drugs with BIC/FIC potential, such as mAbs and engineered immune cells. The company collaborates with leading international labs and R&D teams including Ruizhi Medicine and the Institute of Immunology at Shanghai University of Science and Technology. The company's strategy is to harness the power of innate immunity, particularly NK cells, to fight the spread of cancer cells. |